Abbvie ((ABBV)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is conducting a Phase 3 clinical study titled A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17). The study aims to assess the safety and effectiveness of ubrogepant, a drug approved for adults, for treating migraines in children and adolescents aged 6-17. This research is significant as migraines are common and debilitating in this age group.
The intervention being tested is ubrogepant, an oral tablet designed to treat acute migraine attacks. The study involves two cohorts: a pharmacokinetic (PK) cohort for dose determination and a main study cohort for efficacy testing, with participants receiving either a low or high dose of ubrogepant or a placebo.
The study follows a randomized, parallel assignment model with triple masking (participant, care provider, investigator) to ensure unbiased results. Its primary purpose is treatment-focused, aiming to establish the drug’s efficacy and safety in the target population.
Key dates for this study include its start date on November 8, 2021, and the last update on August 25, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates on its findings.
This study could significantly impact AbbVie’s stock performance and investor sentiment by potentially expanding the market for ubrogepant to younger patients. As the company explores new applications for its existing drugs, this could position AbbVie favorably against competitors in the migraine treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.